Nomegestrol acetate

Nomegestrol acetate
Systematic (IUPAC) name
(17α)-17-acetyl-6-methyl-3-oxoestra-4,6-dien-17-yl acetate
Clinical data
  • ℞ (Prescription only)
Oral
Identifiers
58652-20-3
G03DB04
PubChem CID 91668
ChemSpider 82771
Chemical data
Formula C23H30O4
370.482 g/mol

Nomegestrol acetate (INN; Lutenyl), or 19-normegestrol acetate, is a steroidal progestin with additional antigonadotropic effects which was introduced in 1986 and is used as a hormonal contraceptive.[1][2] Unlike many other steroidal progestogens, it is selective for the progesterone receptor, lacking any significant affinity for other steroid receptors such as the androgen, estrogen, glucocorticoid, and mineralocorticoid receptors. As a result, it does not possess any androgenic, estrogenic, glucocorticoid, or mineralocorticoid effects. However, at sufficiently high doses it does have potent antiestrogenic and antiandrogenic effects due to its progesterone receptor-mediated antigonadotropic properties.[3][4]

The combination with estradiol is also used as a hormonal contraceptive and approved in Europe under the name Zoely.[5]

See also

References

  1. ↑ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1445. ISBN 978-0-412-46630-4. Retrieved 12 May 2012.
  2. ↑ Jamin C, Batallan A, Madelenat P (January 2003). "[Antigonadotropic effects of a 19-nor-progesterone derivative: the example of nomegestrol acetate]". Gynécologie, Obstétrique & Fertilité (in French) 31 (1): 70–81. doi:10.1016/s1297-9589(02)00009-7. PMID 12659788.
  3. ↑ Lello S (March 2010). "Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy". Drugs 70 (5): 541–59. doi:10.2165/11532130-000000000-00000. PMID 20329803.
  4. ↑ Paris J, Thévenot R, Bonnet P, Granero M (1983). "The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative". Arzneimittel-Forschung 33 (5): 710–5. PMID 6683550.
  5. ↑ European Medicines Agency: Zoely